RXL News and Press, ProShares Ultra Health Care From 04/23/19

The Dow reached a 7-month high last Thursday and Nasdaq topped 8,000 on Wednesday as both indexes (and the S&P 500) are only a little over 1% below their all-time highs, set last fall. The biggest news last week was that the Apple ([[AAPL]]) and Qualcomm ([[QCOM]]) settlement on Tues...

Every Thursday night, Bespoke publishes a YTD return for all 11 sectors of the S&P 500, and last Thursday night's bar chart shows that the Healthcare sector was now negative for 2019 YTD, dramatically underperforming the S&P 500 YTD. Using IBES by Refinitiv actual earnings and revenu...

As if here weren't enough things for investors to worry about, a new fear is being talked about on Wall Street. Although corporate earnings are beating expectations, financial commentators are focused on the latest weakness in the healthcare sector. With the stocks of many biotech and pharmace...

Pharmaceutical companies are continuing to defy political pressure from both Democrats and Republicans by raising the prices of almost 3,000 drugs in the U.S. in the first three months of this year. More news on: Health Care Select Sect SPDR ETF, iShares U.S. Healthcare ETF, Vanguard Hea...

By Vinay Thapar Healthcare stocks served as powerful painkillers during last year's market declines. Yet the sector offers much more than just downside protection for investors who focus on business potential and resist the urge to predict scientific breakthroughs. While the MSCI World I...

By Ethan Lovell and Rich Carney, CFA The U.S. Department of Health and Human Services wants to eliminate drug manufacturer rebates in Medicare, a move that could improve affordability for consumers. Portfolio Manager Ethan Lovell and Research Analyst Rich Carney, of the Global Life Scienc...

For those of you investing in Big Pharma, you may want to keep a close eye on developments in Washington over the next two years. The cost of pharmaceuticals may very well be the number one issue leading up to the 2020 election, and this year it may very well be different. This year, the Dem...

By Antonio (Tony) Docal, CFA, Director of Portfolio Management, Templeton Global Equity Group® and Heather Arnold, CFA, Director of Research, Portfolio Manager, Templeton Global Equity Group® The market environment for value investors over the past few years has been less than id...

FOURTH-QUARTER & FULL-YEAR 2018 RESULTS FULL-YEAR 2018 TARGETS ACHIEVED ADJUSTED EBITA UP +6.1% IN FY 2018 AND RECURRING NET INCOME UP IN DOUBLE DIGITS INCREASE IN PROPOSED DIVIDEND TO €0.44 PER SHARE FULL YEAR 2018 TARGETS ACHIEVED Sales of €13.37b...

To be fair, we’re only a little more than halfway through the fourth quarter’s earnings season. Much could still change on the proverbial ‘back nine.’ On the other hand, with most of the major names already reporting last quarter’s results, where we are is ...